Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Laura S. Schmidt, Fuh-Mei Duh, Fan Chen et al. · Nature Genetics · 1997 · 1.5K citations

Medicine, Genetics, Oncology +17

Statistical estimations in pharmacokinetics

Harold Boxenbaum, Sidney Riegelman, Robert M. Elashoff · Journal of Pharmacokinetics and Biopharmaceutics · 1974 · 728 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +6

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

C. Patrick, Ramasamy Jagadeeswaran, Simha Jagadeesh et al. · Cancer Research · 2005 · 578 citations

Medicine, Oncology, Pharmacology +14

Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met–Dependent Human Tumors

Teresa L. Burgess, Angela Coxon, Susanne Meyer et al. · Cancer Research · 2006 · 253 citations

Life Sciences, Oncology, Pharmacology +17

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Alla Danilkovitch‐Miagkova, Berton Zbar · Journal of Clinical Investigation · 2002 · 244 citations · Full text

Medicine, Cancer Biology, Oncology +14